- Home
- GHRS vs ESPR Comparison
GHRS vs ESPR Comparison
Compare GHRS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- ESPR
- Stock Information
- Founded
- GHRS 2018
- ESPR 2008
- Country
- GHRS Ireland
- ESPR United States
- Employees
- GHRS N/A
- ESPR N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- ESPR Health Care
- Exchange
- GHRS Nasdaq
- ESPR Nasdaq
- Market Cap
- GHRS 462.0M
- ESPR 410.2M
- IPO Year
- GHRS 2021
- ESPR 2013
- Fundamental
- Price
- GHRS $8.99
- ESPR $2.15
- Analyst Decision
- GHRS Strong Buy
- ESPR Buy
- Analyst Count
- GHRS 3
- ESPR 5
- Target Price
- GHRS $35.67
- ESPR $5.13
- AVG Volume (30 Days)
- GHRS 89.4K
- ESPR 4.4M
- Earning Date
- GHRS 02-27-2025
- ESPR 02-25-2025
- Dividend Yield
- GHRS N/A
- ESPR N/A
- EPS Growth
- GHRS N/A
- ESPR N/A
- EPS
- GHRS N/A
- ESPR N/A
- Revenue
- GHRS N/A
- ESPR $295,451,000.00
- Revenue This Year
- GHRS N/A
- ESPR $186.04
- Revenue Next Year
- GHRS N/A
- ESPR $11.25
- P/E Ratio
- GHRS N/A
- ESPR N/A
- Revenue Growth
- GHRS N/A
- ESPR 187.12
- 52 Week Low
- GHRS $5.92
- ESPR $1.58
- 52 Week High
- GHRS $14.99
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- GHRS 58.18
- ESPR 42.65
- Support Level
- GHRS $8.02
- ESPR $2.05
- Resistance Level
- GHRS $10.23
- ESPR $2.31
- Average True Range (ATR)
- GHRS 0.90
- ESPR 0.14
- MACD
- GHRS 0.11
- ESPR 0.01
- Stochastic Oscillator
- GHRS 62.20
- ESPR 28.57
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.